CO2023010264A2 - Compuestos quelantes multiméricos para uso en radioterapia dirigida - Google Patents
Compuestos quelantes multiméricos para uso en radioterapia dirigidaInfo
- Publication number
- CO2023010264A2 CO2023010264A2 CONC2023/0010264A CO2023010264A CO2023010264A2 CO 2023010264 A2 CO2023010264 A2 CO 2023010264A2 CO 2023010264 A CO2023010264 A CO 2023010264A CO 2023010264 A2 CO2023010264 A2 CO 2023010264A2
- Authority
- CO
- Colombia
- Prior art keywords
- moiety
- multimeric
- chelator
- chelating compounds
- multifunctional linker
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000001959 radiotherapy Methods 0.000 title 1
- 239000002738 chelating agent Substances 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001735 carboxylic acids Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 235000018977 lysine Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención cubre compuestos de la fórmula general (I): [(C)n–L]–(V)m (I) en la que C es un quelante y n > 1, L es un resto enlazador multifuncional que comprende múltiples grupos funcionales para la unión covalente de un quelante, tal como un esqueleto que contiene poliamina o poliácido, o un polímero que contiene aminoácido que comprende cadenas laterales con restos amino, tiol o ácido carboxílico, tal como lisina, cisteína o ácido glutámico, y V es un resto de direccionamiento de tejido donde m = 1–5, que se acopla preferentemente a través de un resto de acoplamiento o bien al resto enlazador multifuncional L, o directamente al resto quelante C, y estereoisómeros, tautómeros, N–óxidos, hidratos, solvatos y sales de los mismos, y mezclas de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21154574 | 2021-02-01 | ||
| PCT/EP2022/052170 WO2022162210A1 (en) | 2021-02-01 | 2022-01-31 | Multimeric chelator compounds for use in targeted radiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023010264A2 true CO2023010264A2 (es) | 2023-08-09 |
Family
ID=74494810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0010264A CO2023010264A2 (es) | 2021-02-01 | 2023-08-01 | Compuestos quelantes multiméricos para uso en radioterapia dirigida |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240156999A1 (es) |
| EP (1) | EP4284445A1 (es) |
| JP (1) | JP2024506559A (es) |
| KR (1) | KR20230141776A (es) |
| CN (1) | CN116829197A (es) |
| AU (1) | AU2022212602A1 (es) |
| CA (1) | CA3210027A1 (es) |
| CL (1) | CL2023002226A1 (es) |
| CO (1) | CO2023010264A2 (es) |
| CR (1) | CR20230364A (es) |
| DO (1) | DOP2023000141A (es) |
| EC (1) | ECSP23058352A (es) |
| IL (1) | IL304531A (es) |
| MX (1) | MX2023009004A (es) |
| TW (1) | TW202241526A (es) |
| WO (1) | WO2022162210A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| JP2020515596A (ja) * | 2017-03-30 | 2020-05-28 | コーネル ユニバーシティー | α線放出放射線核種の大環状錯体およびがんの標的放射線療法におけるそれらの使用 |
| JP2021502418A (ja) * | 2017-11-04 | 2021-01-28 | アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド | ポリペプチドを修飾するための組成物及び方法 |
| WO2020106886A1 (en) * | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
-
2022
- 2022-01-28 TW TW111103988A patent/TW202241526A/zh unknown
- 2022-01-31 JP JP2023546496A patent/JP2024506559A/ja active Pending
- 2022-01-31 CN CN202280012425.7A patent/CN116829197A/zh active Pending
- 2022-01-31 EP EP22701407.3A patent/EP4284445A1/en active Pending
- 2022-01-31 CR CR20230364A patent/CR20230364A/es unknown
- 2022-01-31 CA CA3210027A patent/CA3210027A1/en active Pending
- 2022-01-31 WO PCT/EP2022/052170 patent/WO2022162210A1/en active Application Filing
- 2022-01-31 US US18/275,375 patent/US20240156999A1/en active Pending
- 2022-01-31 AU AU2022212602A patent/AU2022212602A1/en active Pending
- 2022-01-31 MX MX2023009004A patent/MX2023009004A/es unknown
- 2022-01-31 KR KR1020237025834A patent/KR20230141776A/ko unknown
-
2023
- 2023-07-17 IL IL304531A patent/IL304531A/en unknown
- 2023-07-24 DO DO2023000141A patent/DOP2023000141A/es unknown
- 2023-07-27 CL CL2023002226A patent/CL2023002226A1/es unknown
- 2023-08-01 CO CONC2023/0010264A patent/CO2023010264A2/es unknown
- 2023-08-01 EC ECSENADI202358352A patent/ECSP23058352A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000141A (es) | 2023-08-31 |
| IL304531A (en) | 2023-09-01 |
| CN116829197A (zh) | 2023-09-29 |
| AU2022212602A9 (en) | 2024-05-30 |
| EP4284445A1 (en) | 2023-12-06 |
| MX2023009004A (es) | 2023-08-08 |
| JP2024506559A (ja) | 2024-02-14 |
| AU2022212602A1 (en) | 2023-07-13 |
| CL2023002226A1 (es) | 2023-12-29 |
| CR20230364A (es) | 2023-10-02 |
| ECSP23058352A (es) | 2023-09-29 |
| KR20230141776A (ko) | 2023-10-10 |
| CA3210027A1 (en) | 2022-08-04 |
| TW202241526A (zh) | 2022-11-01 |
| US20240156999A1 (en) | 2024-05-16 |
| WO2022162210A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113684T1 (el) | Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη | |
| MX2009011783A (es) | Inhibidores de iap. | |
| PE20091575A1 (es) | Derivados bifenilo como inhibidores del virus de la hepatitis c | |
| ATE488771T1 (de) | Massenmarkierungen | |
| RS20090104A (en) | Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors | |
| EP2180027A4 (en) | NOVEL HYDROGEL FORMING AGENT BASED ON LIPID-TRIPEPTIDE AND HYDROGEL | |
| AR064842A1 (es) | Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep | |
| ATE162183T1 (de) | Natürliche aminosäurederivate als metalloproteinase-inhibitoren | |
| AR031305A1 (es) | Agonistas del receptor alfa activado del proliferador de peroxisomas | |
| BR112014029972A2 (pt) | reagentes de conjugação | |
| CY1109883T1 (el) | Υδατικα συγκεντρωματα δραστικων ουσιων με ζιζανιοκτονα δραση | |
| BRPI0609783A8 (pt) | composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto | |
| ES2153028T3 (es) | Derivados de isatina para el teñido de fibras que contienen queratina. | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| WO2009047298A3 (en) | Dimers of harmol or of its derivatives and uses thereof | |
| ATE522516T1 (de) | Inhibitoren der ikk-beta-serin-threonin- proteinkinase | |
| CO5650218A2 (es) | Composiciones de enjuague bucal que contienen sales del alquil ester de n-acil arginina | |
| MY148953A (en) | Substituted biphenyl carboxylic acids and derivatives thereof | |
| ATE492532T1 (de) | Aminosäure- und peptid-konjugate von arylalkylsäuren zur verwendung in der kosmetik | |
| CO2023010264A2 (es) | Compuestos quelantes multiméricos para uso en radioterapia dirigida | |
| CY1119872T1 (el) | Παραγωγα τριαζινης προς χρηση σε μια επουλωτικη θεραπευτικη αγωγη | |
| RS53769B1 (en) | IMMUNOGENIC COMPOUNDS CONTAINING HIV GP41 PEPTID CONNECTED TO CRM197 PROTEIN-NOSIOC | |
| HU0201083D0 (es) | ||
| DK1819704T3 (da) | Pyrrolopyridin-2-carboxylsyre-amid-derivat anvendelig som inhibitor af glycogenphosphorylase | |
| BR0009265A (pt) | Derivados com base em esfingóide e usos destes |